

YOU ARE INVITED TO ATTEND THE
DEFENSE OF THE DOCTORAL
DISSERTATION

“Carbonic anhydrase 1 promotes mast cell development”

by

Everett Henry

Infection, Immunity and Inflammation Program

B.A. 2011, Drew University, NJ

Thesis Advisor, Mark Siracusa, Ph.D.
Assistant Professor
Department of Medicine

Tuesday, January 29th, 2019
11:00 A.M.
Cancer Center G1196

ABSTRACT

Type 2 cytokine-mediated inflammation is necessary for the development of protective immunity to helminth parasites but also causes the inflammation associated with allergies and asthma. Type 2 cytokine responses promote a complex but coordinated interplay of immune cells including hematopoietic stem/progenitor cells (HSPCs) that can differentiate into other type 2-promoting effector cells including mast cells. Further, recent studies have demonstrated that the development of HSPCs into mast cells represents a critical component of the type 2 inflammation. Our transcriptional analysis revealed that elevated carbonic anhydrase (Car) enzyme expression in type 2-associated HSPCs is concomitant with their increased mast cell potential. Here, we show that pharmacologic inhibition of Car enzymes impairs mast cell-dependent immunity to the helminth parasite *Trichinella spiralis* and the induction of mast cell responses in the context of food allergy-like disease. Additionally, HSPCs genetically edited to delete Carbonic anhydrase 1 exhibited a reduced capacity to develop into mast cells. Collectively, these data suggest that Car1 operates as a positive regulator of mast cell development. To further investigate the role that Car1 plays in mast cell lineage commitment, we generated a Car1-enhanced green fluorescent protein (eGFP) reporter mouse model and investigated Car1 expression in stem cell populations. Remarkably, Car1 expression was found to be limited to a small population of progenitor cells in the bone marrow and spleen. Sort-purification of Car1-expressing cells revealed they possessed dual potential to develop into mast cells and erythrocytes. These data support a growing body of literature suggesting that mast cells and erythrocytes share common developmental origins and further highlight the potential of Car1 as a therapeutic target capable of regulating mast cell-mediated inflammation.